跳至主要内容
临床试验/NL-OMON50870
NL-OMON50870
招募中
不适用

Assessment of the safety and performance of the HARPOON* Beating Heart Mitral Valve Repair System; a multi-center post-market study (The ASCEND Study). - HARPOON ASCEND study

HARPOON Medical, an indirect wholly-owned subsidiary of Edwards Lifesciences Corporation0 个研究点目标入组 20 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
未指定
发起方
HARPOON Medical, an indirect wholly-owned subsidiary of Edwards Lifesciences Corporation
入组人数
20
状态
招募中
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
2年前
研究类型
Observational non invasive

研究者

发起方
HARPOON Medical, an indirect wholly-owned subsidiary of Edwards Lifesciences Corporation

入排标准

入选标准

  • Each subject is required to meet all of the following inclusion criteria:
  • 1\. Subject is \> 18 years old
  • 2\. Presence of severe MR as read on a transthoracic echocardiographic study
  • 3\. Mitral leaflet coaptation surface is sufficient to reduce mitral
  • regurgitation without undue leaflet tension (approximate leaflet to gap ratio
  • of 2:1\) based on the judgment of the patient eligibility committee and the
  • operating surgeon
  • 4\. Degenerative mitral valve disease with mid\-segment P2 prolapse
  • 5\. Patient is able to sign informed consent and able to return for follow\-up
  • and is capable of participating in all testing associated with this clinical

排除标准

  • A subject meeting any of the following criteria shall be excluded:
  • 1\. Patient is of the age where further growth is expected
  • 2\. Active endocarditis
  • 3\. Left ventricular or left atrial appendage thrombus
  • 4\. Severe mitral annular and/or leaflet calcification
  • 5\. Cannot tolerate procedural anticoagulation or post\-procedure antiplatelet
  • 6\. Mitral stenosis
  • 7\. Functional Mitral Valve disease
  • 8\. Previous mitral valve replacement surgery
  • 9\. Fragile or thinning apex

结局指标

主要结局

未指定

相似试验